Welcome to the second edition of Market Notes, our biweekly newsletter tracking developments across the startup map entries. The second edition shows that much of the most important progress does not make for sexy headlines. Neuromodulation, quickly developing into a hotbed of commercially attractive innovation, showed acquisitions, new funding, and clinical progress, accounting for half the entries this fortnight on its own.The wider pattern was milestones over megarounds. Capital clustered around commercialization: growth rounds, public offerings, and Series C+ financing tied to companies already carrying regulatory clearances. That shift toward the unglamorous middle of the development cycle is where the Double Click sits this week, with a Belgian startup taking a capital-efficient path through one of the field's hardest problems.
Neuralink recruited Jeffrey J. Kimbell & Associates, a Washington health-lobbying firm, signaling a more active policy posture as the company moves toward higher-volume implantation. The move follows the December hire of David McMullen, who led the FDA's Office of Neurological and Physical Medicine Devices, the unit that reviews neurological implants, as head of medical affairs. Neuralink is building formal regulatory and policy capacity alongside the clinical and manufacturing scale-up seen over the past year.
ReVision Implant closed an oversubscribed €4M round from private investors, including European business leaders and medtech operators alongside existing backers. The Belgian company is building Occular, a visual cortical prosthesis that bypasses the eye to stimulate the visual cortex directly, positioned for patients that retinal implants cannot reach. The raise follows FDA Breakthrough Device designation earlier this year and funds a move from preclinical work toward clinical and operational scale-up. A first short-term clinical test is scheduled for October 2026.
Shiratronics completed enrollment in its study of neuromodulation for chronic migraine. The company develops a fully implantable system targeting the nerves involved in migraine, placing it among a small set of device makers pursuing implant-based treatment for a condition long managed pharmacologically. Completed enrollment moves the study toward the data readout that will define the therapy's clinical profile.
Nyxoah priced a $95M underwritten public offering of 55.2M ordinary shares at $1.72, alongside the start of a transition to a US-based CEO. The company develops the Genio system, a hypoglossal nerve stimulation device for obstructive sleep apnea, and is positioning for US commercial scale-up. The capital raise and leadership shift together frame that pivot toward the US market following regulatory progress.
NeuroPace received FDA approval for its ECoG Assistant, an AI-driven feature for its epilepsy platform. The company's RNS System is a closed-loop implant that records cortical activity and delivers responsive stimulation. The new feature applies AI to the electrocorticography data the device already captures. The approval extends an established implant's value through software and positions NeuroPace within the broader move toward AI-assisted interpretation of long-term neural recordings.
.jpeg)
Neuronoff implanted its first patient in a DoD-funded trial of its Injectrode platform for neurogenic bladder in spinal cord injury. The Injectrode is an injectable electrode designed to deliver neuromodulation without implanted leads, reducing surgical burden. The first implant moves the platform from preclinical validation into human testing.
Resmed completed its acquisition of Noctrix Health, expanding its clinical sleep-health portfolio. Noctrix develops non-invasive peripheral nerve stimulation for restless legs syndrome, an indication with limited device-based options. The deal, announced in April, places a focused neuromodulation therapy inside a large sleep and respiratory platform with established procurement and distribution reach. Alongside the deal, Resmed announced a partnership with Oura, opening its network to Ring wearers.
Nexstim was granted authorization for commercial distribution of its NBS System 6 in Australia. The system uses navigated transcranial magnetic stimulation for diagnostic brain mapping. The Australian clearance extends the company's geographic footprint.
Omniscient secured a $27.2M Series D to accelerate the commercialization of its AI-enabled brain-mapping technology. The company builds software that maps functional brain networks from imaging data, positioned as a tool layer for neurosurgical planning and neurological care. The round signals investor appetite for the analytics and infrastructure side of neuroimaging, where value accrues to interpretation rather than acquisition. The funding also coincides with a new CPT code, signalling work on the reimbursement layer.
Subtle Medical secured $33M in growth capital led by Morgan Stanley Expansion Capital, bringing total funding to roughly $86M, and named a new CEO. Co-founder Enhao Gong moves to chief science officer. The raise follows FDA clearance days earlier for SubtleHD, its next-generation AI PET image-enhancement product. Subtle wants to become a vendor-neutral AI infrastructure layer for medical imaging spanning MR, PET, and a planned expansion into CT. The leadership change alongside the capital frames a transition from R&D-led growth toward commercial scaling.
SOND exited stealth with $7M and introduced Dreambuds, a closed-loop in-ear system that captures twelve physiological signals overnight and adapts audio in real time through a cloud-based AI coach. The company was founded by Yadid Ayzenberg, Bose's former head of sleep products, and the round drew E14 Fund, Crosslink Capital, Ubiquity Ventures, and Boston Scientific co-founder John Abele. Mass production is targeted for Q2 2026 following a planned crowdfunding campaign. The launch drew substantial interest. Interestingly, the Dreambuds do not seem to integrate electrodes to measure the brain directly.
.svg)
